Automating {UML} Models Merge for Web Services Testing

International audienceThis paper presents a method for merging UML models which takes place in a quality evaluation framework for Web Services (WS). This framework, called iTac-QoS, is an ex- tended UDDI server (a yellow pages system dedicated to WS), using model based testing to assess quality. WS ven- dors have to create UML model of their product and our framework extracts tests from it. Depending on the results of the test execution, a mark is given to WS. This mark per- mits to customers to have an idea about the quality of WS they find on our UDDI server. Up today, our framework was limited to WS which did not use other WS. This was justified by the fact that it is im- possible for vendors to create a good model of a foreign product. Our method for model merging solves this prob- lem: each vendor produces models of its own product, and we automatically merge the different models. The resulting model from this merging represents the composition of the different WS. For each type of diagram present in the models (class, instance or state-chart diagram), a method is proposed in order to produce a unique model. In addition to this, a solu- tion is proposed to merge all OCL code in the class modeling the WS under test. Unfortunately, this process introduces inconsistencies in the resulting model, that falsify the results of the subsequent test generation phase. We thus propose to detect such inconsistencies in order to distinguish incon- sistent and unreachable test targets

A Video Transmission Framework Using Components and Multi-Agent Systems

International audienceThis paper presents an application of video transmission over Internet, which goal is to be used in a cooperative plat- form. This application uses proxies during the transmission to adapt the video (changing the size, the framerate and/or the encoding format). Adaptation is a necessity in this kind of application, due to the diversity of receivers (computers, mobile phones, PDA . . . ). During the design process, we chose to use component ori- ented programming and multi-agent systems. We present here how these two paradigms help us to have a flexible and evolutive application, and, for each transmission?s step, what is the most appropriated solution. At the end, we also present tests that have been made to evaluate the power needed by the proxies in order to discuss about benefits that can be brought by our architecture

Automated UML models merging for web services testing

International audienceThis paper presents a method for merging UML models which takes place in a quality evaluation framework for Web Services (WS). This framework, called iTac-QoS, is an extended UDDI server (a yellow pages system dedicated to WS), using model based testing to assess quality. WS vendors have to create UML model of their product and our framework extracts tests from it. Depending on the results of the test execution, a mark is given to WS. This mark gives to the cus- tomers an idea about the quality of WS they find on our UDDI server. Up today, our framework was limited to WS which did not use other WS. This was justified by the fact that it is impossible for vendors to cre- ate a good model of a foreign product. Our method for model merging solves this problem: each vendor produces models of its own product, and we automatically merge the different models. The resulting model from this merging represents the composition of the different WS. For each type of diagram present in the models (class, instance or state- chart diagram), a method is proposed in order to produce a unique model. In addition to this, a solution is proposed to merge all OCL code in the class modeling the WS under test. Unfortunately, this pro- cess introduces inconsistencies in the resulting model, that falsify the results of the subsequent test generation phase. We thus propose to detect such inconsistencies in order to distinguish inconsistent and un- reachable test targets

EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)

Patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) have a poor prognosis, and their management represents a substantial unmet medical need. Preclinical data and results from a phase Ib trial demonstrated the efficacy and tolerability of the combination of the α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib plus the poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib in platinum-resistant, non-BRCA-mutated ovarian cancer. Here, we describe the study design and rationale for the phase III, multicenter, open-label, randomized, active-controlled EPIK-O/ENGOT-OV61 trial investigating alpelisib in combination with olaparib compared with standard-of-care chemotherapy in patients with platinum-resistant or -refractory HGSOC with no germline BRCA mutation. Progression-free survival (blinded independent review committee) is the primary end point. Overall survival is a key secondary end point

Interleukin-1 (IL-1) and the inflammasome in cancer

Inflammation is a hallmark of cancer and while exciting preclinical and clinical data has emerged implicating inflammation in the development and progression of certain cancer, our mechanistic understanding of how distinct inflammatory pathways are contributing to specific stages and types of cancer is still at an early stage. Malignancies are known to arise in areas of chronic inflammation and inflammation in the tumor microenvironment (often called tumor-promoting inflammation) is believed to allow cancer cells to evade immunosurveillance while promoting genetic instability, survival and progression. Among the strongest data suggesting a causal role for inflammation in cancer comes from the recent CANTOS trial which demonstrated that chronic IL-1β inhibition with canakinumab leads to a significant, dose-dependent decrease in incident lung cancer. This observation has launched a series of additional clinical studies to understand the role of IL-1β and inflammasome in cancer and when, during the course of disease progression, inhibition of IL-1β provides patients with disease altering benefit. In this article we will review recent data implicating IL-1β signaling and its upstream regulator NLRP3 in both solid tumor and hematologic malignancies. We will discuss the key preclinical observations and the current clinical landscape, and describe the pharmacologic tools which will be used to evaluate the effects of blocking tumor-promoting inflammation clinically